Eyedentity, a Stockholm startup using AI to catch deadly eye disease earlier, has secured €1.3M in a round led by Norrsken Launcher, with participation from Karolinska Institutet Innovation and a group of angel investors.
Founded in 2025, the company develops software that detects serious eye conditions from fundus images already captured during routine examinations at opticians. Co-founder and chief scientific officer Gustav Stålhammar notes that opticians are taking an ever-larger number of images and seeing a growing patient pool, yet many sight-threatening diseases go unnoticed until symptoms appear.
The technology targets conditions like uveal melanoma, a rare but deadly eye cancer where earlier detection dramatically improves outcomes. By flagging suspicious scans during a routine visit, Eyedentity aims to shift diagnosis from the clinic to the high street, where most people first have their eyes checked.
Norrsken Launcher partner Anna Fredrixon frames the pitch as technology that saves lives without adding pressure to an overburdened healthcare system, since it works on images that are already being captured.
The funding lands amid a busy 2026 for European AI diagnostics startups, with nearly €70M flowing to medical imaging and early detection companies, according to EU-Startups.
Eyedentity will use the capital to refine its algorithms, build clinical evidence and prepare the product for wider deployment with optical chains and healthcare providers.
